Purchase of Telaprevir
Milestone Payments from
September 2009
Athyrium Capital Managment, LLC
Purchase of Telaprevir Milestone Payments
from Vertex Pharmaceuticals Incorporated
[Press Release]
Purchase of Telaprevir Milestone Payments
from Vertex Pharmaceuticals Incorporated
[Press Release]
Announced: September 2009Headquarters: New York, NY
Managing Member: Jeffrey Ferrell
Athyrium Capital is a life sciences focused investment and advisory company with offices in New York City. Acting as exclusive buyside advisor, Torreya represented Athyrium in its cash purchase of future telaprevir milestone payments. As part of the transaction, Vertex received approximately $35 million in cash for the sale of up to $95 million of rights to potential future milestone payments that Vertex is eligible to receive from Janssen Pharmaceutica for the launch of Vertex's hepatitis C virus protease inhibitor telaprevir in Europe.
Copyright © 2010 Torreya Partners LLC. All rights reserved.
Securities offered through Financial West Group, member FINRA/SIPC. Torreya Partners LLC and Financial West Group are unaffiliated entities.